AC Immune SA (ACIU): Price and Financial Metrics


AC Immune SA (ACIU): $7.93

0.49 (+6.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACIU POWR Grades


  • ACIU scores best on the Value dimension, with a Value rank ahead of 55.71% of US stocks.
  • The strongest trend for ACIU is in Momentum, which has been heading down over the past 31 weeks.
  • ACIU's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

ACIU Stock Summary

  • The ratio of debt to operating expenses for AC Immune SA is higher than it is for about just 6.58% of US stocks.
  • With a year-over-year growth in debt of 269.49%, AC Immune SA's debt growth rate surpasses 96.18% of about US stocks.
  • Over the past twelve months, ACIU has reported earnings growth of 881.2%, putting it ahead of 97.64% of US stocks in our set.
  • Stocks that are quantitatively similar to ACIU, based on their financial statements, market capitalization, and price volatility, are USEG, MMYT, UTSI, TACT, and BB.
  • ACIU's SEC filings can be seen here. And to visit AC Immune SA's official web site, go to www.acimmune.com.

ACIU Price Target

For more insight on analysts targets of ACIU, see our ACIU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.88 Average Broker Recommendation 1.38 (Strong Buy)

ACIU Stock Price Chart Interactive Chart >

Price chart for ACIU

ACIU Price/Volume Stats

Current price $7.93 52-week high $13.00
Prev. close $7.44 52-week low $4.42
Day low $7.28 Volume 846,000
Day high $7.93 Avg. volume 764,952
50-day MA $6.69 Dividend yield N/A
200-day MA $6.39 Market Cap 576.14M

AC Immune SA (ACIU) Company Bio


AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.


ACIU Latest News Stream


Event/Time News Detail
Loading, please wait...

ACIU Latest Social Stream


Loading social stream, please wait...

View Full ACIU Social Stream

Latest ACIU News From Around the Web

Below are the latest news stories about AC Immune SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.

AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile

AC Immune SA (NASDAQ: ACIU ) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirming earlier interim results. The company will complete the Phase 2 study with the 24-month … Full story available on Benzinga.com

Benzinga | June 2, 2021

Thinking about buying stock in AC Immune, Ashford Hospitality Trust, Sorrento Therapeutics, Jaguar Health, or Exela Technologies?

NEW YORK , June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACIU, AHT, SRNE, JAGX, and XELA.

Benzinga | June 2, 2021

AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer's disease LAUSANNE, Switzerland, June 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU ), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided key clinical and preclinical updates for its SupraAntigen ® -derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta (Abeta). AC Immune is completing a Phase 2 study of its first clinical candidate, ACI-24, in people with mild Alzheimer's disease (AD), an...

Benzinga | June 2, 2021

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease LAUSANNE, Switzerland, June 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided key clinical and preclinical updates for its Su

Yahoo | June 2, 2021

Alzheimer's Disease Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook

Los Angeles, USA, May 31, 2021 (GLOBE NEWSWIRE) -- Alzheimer's Disease Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook Alzheimer's Disease pipeline shows progress in the clinical trials with the upcoming therapies such as BAN2401, Gantenerumab, Bryostatin-1, INB03, AZT-211, and others. DelveInsight's " Alzheimer's Disease Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Alzheimer's Disease pipeline landscapes. It comprises Alzheimer's Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer's Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer's Disease...

Benzinga | May 31, 2021

Read More 'ACIU' Stories Here

ACIU Price Returns

1-mo 25.87%
3-mo 2.85%
6-mo 43.92%
1-year 10.45%
3-year -13.80%
5-year N/A
YTD 53.38%
2020 -39.32%
2019 -9.84%
2018 -26.17%
2017 -1.39%
2016 N/A

Continue Researching ACIU

Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:

AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9187 seconds.